Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-Pharmaceuticals

More Like This

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

PR Newswire associated0

TLX101-Px (Pixlumi®) MAA Accepted in Europe

PR Newswire associated0

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

PR Newswire associated0

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

PR Newswire associated0

Telix Announces Reorganisation to Deliver on Strategic Priorities

PR Newswire associated0

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

PR Newswire associated0

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent